Health
Combo monoclonal antibody drugs may lower coronavirus loads – CIDRAP
Bamlanivimab paired with etesevimab was more effective than bamlanivimab alone.
Mildly to moderately ill COVID-19 adult outpatients given a combination of the monoclonal antibodies bamlanivimab and etesevimab early in the disease had significantly lower viral loads at day 11 than those who received a placebo, but a similar effect was not seen in those given bamlanivimab alone, a study published today in JAMA finds.
Bamlanivimab manufacturer Eli Lilly sponsored the double-blind phase 2/3 BLAZE-1 clinical trial, which involved 533 COVID-19 patients at 49 US medical centers. The…
-
General18 hours agoIran’s currency at record low as tensions run high
-
Noosa News24 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
General18 hours agoLabor to pledge $2.3 billion to subsidise home batteries
-
General24 hours ago307,000 Voices | The Spectator Australia